<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mater.</journal-id>
<journal-title>Frontiers in Materials</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mater.</abbrev-journal-title>
<issn pub-type="epub">2296-8016</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">763297</article-id>
<article-id pub-id-type="doi">10.3389/fmats.2021.763297</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Materials</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Smart Chimeric Lysin ClyC Loaded Alginate Hydrogel Reduces <italic>Staphylococcus aureus</italic> Induced Bone&#x20;Infection</article-title>
<alt-title alt-title-type="left-running-head">Yao et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Chimeric Lysin ClyC Loaded Hydrogel</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yao</surname>
<given-names>Fangfang</given-names>
</name>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Xinyu</given-names>
</name>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liao</surname>
<given-names>Yilin</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yan</surname>
<given-names>Qi</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1311297/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Yuhong</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1366161/overview"/>
</contrib>
</contrib-group>
<aff>The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine, Ministry of Education, School of Stomatology, Wuhan University, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1047091/overview">Yijing Liu</ext-link>, Huazhong University of Science and Technology, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1459803/overview">Qianqian Liu</ext-link>, Wuhan Institute of Technology, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/761780/overview">Qianqian Ni</ext-link>, Nanjing University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Qi Yan, <email>yanqi@whu.edu.cn</email>; Yuhong Li, <email>1004809372@whu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Smart Materials, a section of the journal Frontiers in Materials</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>8</volume>
<elocation-id>763297</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Yao, Wu, Liao, Yan and Li.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Yao, Wu, Liao, Yan and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>
<italic>Staphylococcus aureus</italic> (<italic>S. aureus</italic>) is the most common cause of hospital and community-acquired infections. The current clinical treatment is limited by the emergence of drug-resistant strains. We previously developed a chimeric ClyC that effectively inhibited <italic>S. aureus</italic> strains. Nonetheless, an efficient delivery system to provide sustained release of ClyC to infected site is needed. Thus, we engineered a chimeric ClyC loaded alginate hydrogel (ClyC-AH) to improve the therapeutic outcomes against <italic>S. aureus</italic>. ClyC-AH retained the stability and activity of ClyC while providing a sustained release of ClyC and a continuous antibacterial effect against <italic>S. aureus.</italic> Compared to ClyC alone, the use of ClyC-AH was relatively safe, as there was no significant cytotoxicity to BHK-21 cells at a ClyC concentration&#x2264;250&#xa0;&#x3bc;g/ml. Furthermore, in a <italic>S. aureus</italic> infected mouse model of osteomyelitis, ClyC-AH reduced bacterial burden in the femur and surrounding tissues, with a reduction of 2 log<sub>10</sub> (CFU/ml) in viable bacterial number. Based on these results, hydrogel-delivered chimeric lysin ClyC provides a promising future in the <italic>S.aureus</italic> targeting therapy.</p>
</abstract>
<kwd-group>
<kwd>
<italic>Staphylococcus aureus</italic>
</kwd>
<kwd>MRSA</kwd>
<kwd>osteomyelitis</kwd>
<kwd>anti-bacterial activity</kwd>
<kwd>bacteriophage lysin</kwd>
<kwd>alginate hydrogel</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Outstanding Youth Science Fund Project of National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/100014717</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>
<italic>Staphylococcus aureus</italic> (<italic>S. aureus</italic>) is a Gram-positive pathogen that primarily colonizes on the nostrils, skin, and mucosal membranes of human (<xref ref-type="bibr" rid="B26">Lowy, 1998</xref>; <xref ref-type="bibr" rid="B3">Becker and Bubeck Wardenburg, 2015</xref>). <italic>S. aureus</italic> is the main conditional pathogen contributing to hospital and community-acquired infections, leading to infectious diseases such as osteomyelitis (<xref ref-type="bibr" rid="B33">Favero, 2003</xref>; <xref ref-type="bibr" rid="B25">Lindsay and Holden, 2004</xref>).</p>
<p>Osteomyelitis is a challenging infectious medical condition for orthopaedic surgeons (<xref ref-type="bibr" rid="B23">Lew and Waldvogel, 2004</xref>; <xref ref-type="bibr" rid="B27">Maffulli et&#x20;al., 2016</xref>). Approximately 44% of the osteomyelitis are caused by <italic>S. aureus</italic> (<xref ref-type="bibr" rid="B20">Kremers et&#x20;al., 2015</xref>), through hematogenous infection or the spread of a contiguous source. Treatment for osteomyelitis mainly include use of antibiotics and surgical debridement (<xref ref-type="bibr" rid="B5">Conterno and Turchi, 2013</xref>). However, <italic>S. aureu</italic> could directly invade and colonize the osteocyte lacuno-canicular network (<xref ref-type="bibr" rid="B27">Maffulli et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B38">Urish and Cassat, 2020</xref>; <xref ref-type="bibr" rid="B11">Gimza and Cassat, 2021</xref>), which might bring difficulty to anti-infectious treatment. In addition, the pathogenic characteristics of <italic>S. aureu</italic>, including biofilm formation, transmission of drug-resistant genes, and intracellular survival (<xref ref-type="bibr" rid="B30">Pantosti et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B7">Davies and Davies, 2010</xref>; <xref ref-type="bibr" rid="B28">Munita and Arias, 2016</xref>), further limit the therapeutic outcomes. Thus, finding novel antibacterial agents against <italic>S. aureus</italic> has captured the attention of scientists in recent&#x20;years.</p>
<p>Endolysins are enzymes encoded by bacteriophages, which specifically target and degrade the peptidoglycan externally, to cleave bacteria (<xref ref-type="bibr" rid="B14">Haddad Kashani et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B13">Gondil et&#x20;al., 2020b</xref>). Endolysins have strong bactericidal activity and low susceptibility to resistance. Thus, they are emerging as a viable alternative to antibiotics (<xref ref-type="bibr" rid="B1">Abdelrahman et&#x20;al., 2021</xref>). Some endolysins are successfully applied in clinical trials. CF-301 has showed impressive results in treating patients with <italic>S.aureus</italic> bloodstream infections and endocarditis. Furthermore, CF-301 has been used in phase 3 clinical trials, indicating the potential effect of endolysins on bacterial infections (<xref ref-type="bibr" rid="B17">Jun et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B10">Fowler et&#x20;al., 2020</xref>).</p>
<p>ClyC, a novel chimeric lysin, has specificity and robust killing efficacy against drug-resistant and susceptible <italic>S. aureus</italic> and other <italic>staphylococcal</italic>, the effect of which could be further enhanced with calcium. Also, ClyC protected mice from lethal systemic <italic>S. aureus</italic> infection (<xref ref-type="bibr" rid="B24">Li et&#x20;al., 2021</xref>). However, the effect of endolysins are limited by its instability and short half-life <italic>in vivo</italic>, as well as the cytotoxicity tested <italic>in&#x20;vitro</italic> (<xref ref-type="bibr" rid="B34">Resch et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B37">Seijsing et&#x20;al., 2018</xref>). Thus, a suitable delivery mechanism is required to prevent ClyC from degradation, enhance the biocompatibility, and facilitate ClyC entry into the infection sites (<xref ref-type="bibr" rid="B31">Pinto et&#x20;al., 2021</xref>).</p>
<p>Alginate is a linear copolymer derived from brown seaweed that contains repeating units of &#x3b2;-1,4-linked D-mannuronic acid and L-guluronic acid residues. Alginate hydrogels are widely used in wound dressing and bone and cardiac tissue engineering due to their biocompatibility, low cytotoxicity, low immunogenicity, and biodegradability (<xref ref-type="bibr" rid="B35">Ruvinov and Cohen, 2016</xref>; <xref ref-type="bibr" rid="B39">Varaprasad et&#x20;al., 2020</xref>). They are ideal materials for the delivery of protein drugs because they can be prepared under mild pH and temperature conditions (<xref ref-type="bibr" rid="B21">Lee and Mooney, 2012</xref>). Antibacterial agents have been encapsulated in alginate hydrogel in order to target specific pathogens and reduce infections. LysMR-5 incorporated into alginate-chitosan nanoparticles recently exhibited enhanced bactericidal activity against <italic>S. aureus in&#x20;vitro</italic>, but its stability was not assessed in that study (<xref ref-type="bibr" rid="B18">Kaur et&#x20;al., 2020</xref>).</p>
<p>In this study, we designed ClyC loaded alginate hydrogel (ClyC-AH) to treat osteomyelitis caused by <italic>S. aureus</italic> (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). Through the encapsulation process, the stability and bactericidal activity of endolysin were optimized. We hypothesized that the ClyC-AH could sustainably release ClyC, which process the property of ClyC remained stable and the cytotoxicity reduced. Furthermore, we tested the efficacy of ClyC-AH in a <italic>S. aureus</italic> infected osteomyelitis mouse model. The change of bacteria colony forming unit (CFU) was tested to demonstrate the therapeutic potential of the ClyC-AH.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The overall experiment design of the study. 2&#xa0;&#xb5;L <italic>S. aureus</italic> was injected into the marrow cavity for creating an osteomyelitis model. A hydrogel loaded with ClyC was synthesized. ClyC would target and cleave the cell wall conserved domain, leading to lysis. ClyC resulted in infection reduction.</p>
</caption>
<graphic xlink:href="fmats-08-763297-g001.tif"/>
</fig>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Preparation of ClyC-AH</title>
<p>The chimeric lysin, ClyC, was expressed as described previously (<xref ref-type="bibr" rid="B24">Li et&#x20;al., 2021</xref>). Concentration of ClyC was determined by BCA assay and visualized by SDS-PAGE. The ClyC protein solution was freeze-dried and then stored at &#x2212;80&#xb0;C until use. An optimized ClyC-AH formulation was prepared using a one-step procedure at room temperature as proposed by Deng and Feng (<xref ref-type="bibr" rid="B8">Deng et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B9">Feng et&#x20;al., 2020</xref>), with slight modification. Briefly, sodium alginate was dissolved in distilled water and magnetically stirred for 3&#xa0;h until it completely dissolved. Freeze-dried ClyC was mixed with 0.68% calcium chloride solution (Hushi, Shanghai, China). Then, the mixture was added into 1.5% alginate solution at a ratio of 1:1 (v/v) and homogenized. The gelation time was measured by the inversion tube method at room temperature. In brief, 400&#xa0;&#x3bc;L ClyC-AH was taken in a 1.5-ml Eppendorf tubes and incubated at room temperature. The gelation time was confirmed by inverting the tube every 5&#xa0;s until the gel stopped flowing. Each solution was filtered separately through a sterile 0.22-&#x3bc;m membrane into a sterile container.</p>
</sec>
<sec id="s2-2">
<title>Scanning Electron Microscopy</title>
<p>Hydrogel alone and ClyC-AH were separately immersed in Tris buffer at room temperature until reached swelling equilibrium, cut into sections (10&#xa0;mm &#xd7; 7&#xa0;mm &#xd7; 5&#xa0;mm). The samples were lyophilized using the LyoBeta 6&#xa0;PL (Telstar, Spain) instrument, coated with gold (Hummer VI; Technic Inc., Anaheim, CA, United&#x20;States). The microstructure of the sample was evaluated using the SEM (SU8010, Hitachi, Japan) at an accelerating voltage of 3&#xa0;kv.</p>
</sec>
<sec id="s2-3">
<title>Cytotoxicity Test</title>
<p>The toxicity of ClyC released from hydrogel was evaluated using the CCK-8 assay. Alginate hydrogels with different ClyC concentrations (0, 31.25, 62.5, 125, 250, 500, and 1,000&#xa0;&#x3bc;g/ml) were incubated in equal-volume Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM; Sigma, United&#x20;States) at 37&#xb0;C. After 24 and 48&#xa0;h, the whole medium was collected. To investigate the cytotoxicity of the ClyC in the harvested medium, Baby hamster Syrian kidney (BHK)-21 cells were used. The cells were cultured in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37&#xb0;C under 5% CO<sub>2</sub>. BHK-21 cells were seeded into 96-well at a density of 1&#x20;&#xd7; 10<sup>4</sup> cells/well. After 24&#xa0;h, the cell culture medium was exchanged with the harvested medium (100&#xa0;&#xb5;L) and the same concentration of soluble ClyC as a control. After incubation for 24&#xa0;h, the cell viability was measured by CCK-8 assay. The normal cell culture medium without ClyC was used as a positive control (PC), while medium without ClyC and BHK-21 cells served as a negative control (NC). The relative cell viability was determined by using the formula: %cytotoxicity &#x3d; [1- (OD<sub>sample</sub>&#x2013;OD<sub>NC</sub>)/(OD<sub>PC</sub>&#x2013;OD<sub>NC</sub>)] &#xd7;&#x20;100%.</p>
</sec>
<sec id="s2-4">
<title>Determination of the Amount of ClyC Released From Alginate Hydrogels</title>
<p>To investigate the release amount of ClyC from alginate hydrogels, the ClyC-AH (250&#xa0;&#xb5;g/ml, 400&#xa0;&#xb5;L) was incubated in Tris buffer (100&#xa0;&#xb5;L in 1.5-ml Eppendorf tubes) at 37&#xb0;C. At predesignated time intervals (1, 3, 6, 10, 14, 24, 36, 48, and 72&#xa0;h). At each timepoint, the supernatant was sampled, and the same volume of fresh Tris buffer was added. The amount of released ClyC from alginate hydrogels at each time point was determined using the BCA method and calculated based on the standard curve. The structural integrity of ClyC after release was examined using SDS-PAGE analysis. The ClyC released from hydrogel was suspended in SDS-PAGE loading buffer, destabilized by boiling for 10&#xa0;min, processed and analyzed by SDS-PAGE, following standard protocol. Free native ClyC was also processed similarly and analyzed along with the test sample as a reference.</p>
</sec>
<sec id="s2-5">
<title>The Anti-Bacterial Activity Assays of ClyC Released From Alginate Hydrogels</title>
<p>The bacteria strain used in the study was <italic>S. aureus</italic> T23. The inoculum was prepared by culturing <italic>S.aureus</italic> T23 overnight in lysogeny broth (LB) medium with shaking at 37&#xb0;C, washing three times in Tris buffer, by centrifugation, and adjusting the optical density at OD<sub>600</sub> (Synergy H1). A preliminary assessment of the anti-bacterial effect of ClyC released from hydrogel was conducted <italic>via</italic> turbidity reduction experiment and inhibition zone method. For turbidity reduction experiment, the decrease of samples in OD<sub>600</sub> was monitored by a Synergy H1 microplate reader every 1&#xa0;min for 10&#xa0;min at 37&#xb0;C. For the inhibition zone method, 10&#xa0;&#x3bc;L ClyC and ClyC-AH were spotted onto agar plates overlaid with T23 and incubated overnight at 37&#xb0;C. Bactericidal activity was assessed by clear zones on the agar plates. Comparison of bactericidal activity of different timepoint sample was done by measuring colony count. Samples from each timepoint (50&#xa0;&#xb5;L) incubated with 50&#xa0;&#xb5;L T23 inoculum at 37&#xb0;C for 1&#xa0;h, serial dilution, and plating on lysogeny broth agar. Free ClyC solutions (125&#xa0;&#x3bc;g/ml) incubated at 37&#xb0;C were also prepared at each timepoint.</p>
</sec>
<sec id="s2-6">
<title>
<italic>In vivo</italic> Treatment of Osteomyelitis With ClyC-AH</title>
<p>This study was approved by the Ethics Committee for Animal Research, Wuhan University, China (No. 2019A79). C57BL/6 mice were housed in 12-h light/dark cycles and freely provided food and water. The mice were assigned to four groups (bacteria infected, bacteria infected with hydrogel alone, bacteria infected with soluble ClyC alone, and bacteria infected with ClyC-AH groups; <italic>n</italic>&#x20;&#x3d; 5 or 6 per group). Briefly, after anesthetized, the skin on the right knee of mice was shaved and sterilized with 75% alcohol. A lateral incision was made, and the muscle was bluntly dissected to expose the femur. The proximal end of the femur was perforated using a high-speed drill with a 0.5-mma sterile round bur (<xref ref-type="bibr" rid="B4">Cassat and Skaar, 2013</xref>; <xref ref-type="bibr" rid="B19">Klopfenstein et&#x20;al., 2021</xref>). T23 (3 &#xd7; 10<sup>6</sup> cell CFU/mL in 2&#xa0;&#x3bc;L of PBS) was inoculated into the medullary cavity of the femur using 10&#xa0;&#x3bc;L-pipet tips and then injected 5&#xa0;&#x3bc;L of different treatments. For animals receiving hydrogel alone, the hydrogel was pipetted over the hole to polymerize. For animals receiving soluble ClyC, the concentration of ClyC was equal to that of ClyC-AH. Then the wound was double-stitched by surgical silk suture.</p>
<p>After 1 week, all mice were sacrificed. The skin on the right hind leg was disinfected with 75% alcohol. After making a lateral incision, the femur and surrounding tissue were separated, weighed, and placed in 1.5-ml microcentrifuge tubes (with saline). Following dissection and removal, all samples were maintained on ice. The tissue and femur samples were subsequently homogenized using the MD100 by bead beating (5,000&#xa0;rpm, 20&#xa0;s) (NewZongKe, China) (<xref ref-type="bibr" rid="B16">Johnson et&#x20;al., 2018</xref>). Water bath sonication was used to create single-cell bacterial suspensions after homogenization (sonicate 10&#xa0;min, vortex 30&#xa0;s). Homogenates were serially diluted, plated on Baird-Parker agar, and incubated overnight at 37&#xb0;C. Colonies were acounted, normalized to sample weight, and transformed using the formula CFU &#x3d; log<sub>10</sub> (1 &#x2b; X) to avoid negative values.</p>
</sec>
<sec id="s2-7">
<title>Statistics Analysis</title>
<p>Experimental data were expressed as mean&#x20;&#xb1; standard deviation. Statistical analyses were conducted using Prism v 8.0.2 (GraphPad Software, United&#x20;States). Statistical comparisons between two groups were made with Student&#x2019;s t&#x20;test. ANOVA for multivariate parametric data with a Tukey&#x2019;s post hoc test or a Kruskal&#x2013;Wallis test with Dunn&#x2019;s post hoc test for nonparametric data. <italic>p</italic>-value of &#x3c;0.05 was considered as statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Result</title>
<sec id="s3-1">
<title>Characterization of the ClyC-AH</title>
<p>ClyC-AH were prepared simply by mixing 1.5% alginate solution and 0.68% calcium chloride solution-containing ClyC, which was the most common method to prepare the hydrogel from the sodium alginate solution (<xref ref-type="bibr" rid="B21">Lee and Mooney, 2012</xref>). From a macroscopic view, there was no significant difference between ClyC-AH and alginate hydrogel without ClyC, which were both transparent and colorless (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>). The morphology of the samples was observed using SEM. The surface morphology of hydrogel alone and ClyC-AH was similar, which showed porous structure with good continuity. There were tiny pores observed in the structure which was thought to be beneficial for the sustain ClyC release (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>). The gelation time of ClyC-hydrogel was about 20&#xa0;s, short but sufficient for injection into the lesion (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). Meanwhile, it was conducive for the rapid fixation of ClyC-AH in the lesion.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Characterization of the ClyC-AH. <bold>(A)</bold> Images of the hydrogel and ClyC-AH at room temperature; <bold>(B)</bold> Gelation time showing the solution-gel transition of ClyC-AH; <bold>(C)</bold> Surface morphologies of hydrogel and ClyC-AH by SEM.</p>
</caption>
<graphic xlink:href="fmats-08-763297-g002.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>ClyC-AH Reduced ClyC Cytotoxicity</title>
<p>Considering that high concentration of ClyC could cause cytotoxicity in the local infection, we loaded ClyC into alginate hydrogels. The results showed that the cytotoxicity of ClyC-AH was reduced compared with soluble ClyC (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>). At 24&#xa0;h after incubation, with the concentration of ClyC up to 250&#xa0;&#x3bc;g/ml, the cytotoxicity of ClyC-AH showed no significant difference among different concentrations. Soluble ClyC alone had toxic effect on BHK-21 cells. Compared with soluble ClyC, ClyC-AH significantly improved cell viability. It could be explained by the slow release of ClyC from alginate hydrogels. The results suggested that the blank and loaded 250&#xa0;&#x3bc;g/ml ClyC-AH were not cytotoxic to BHK-21&#x20;cells.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Cytotoxicity of ClyC-AH and free ClyC to BHK-21 cells. Firstly, DMEM incubated with ClyC-AH (0, 31.25, 62.5, 125, 250, 500, and 1,000&#xa0;&#xb5;g/ml) for 24&#xa0;h <bold>(A)</bold> and 48&#xa0;h <bold>(B)</bold>. Then cells were co-cultured with incubated DMEM and different concentrations of free ClyC (0, 15.625, 31.25, 62.5, 125, 250, 500 and 1,000&#xa0;&#xb5;g/ml) for 24&#xa0;h. The relative viability was calculated by the change of OD<sub>450</sub> by CCK-8&#x20;assay.</p>
</caption>
<graphic xlink:href="fmats-08-763297-g003.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>
<italic>In vitro</italic> Release of ClyC From Alginate Hydrogels</title>
<p>The amount of ClyC released from the alginate hydrogels are showed in <xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>. After 72&#xa0;h, the cumulative released amount of ClyC from alginate hydrogels was approximately 23&#x20;&#xb1; 0.45%. To test the structural integrity of ClyC released from the alginate hydrogels, SDS-PAGE analysis was used and showed a single band corresponding to the molecular weight of free ClyC, as could be seen in <xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>. No additional band below the ClyC from the alginate hydrogels band, proving that ClyC was not hydrolyzed or degraded during the process of hydrogel gelation and release.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>
<italic>In vitro</italic> release of ClyC from hydrogel at 37&#xb0;C in Tris buffer. <bold>(A)</bold> The curve of percent released ClyC at different time intervals. Mean&#x20;&#xb1; SD, <italic>n</italic>&#x20;&#x3d; 3; <bold>(B)</bold> SDS-PAGE of free ClyC and ClyC released from hydrogel to determine the structural integrity of endolysin after encapsulation. Lane 1: Standard Protein Marker. Lane 2: ClyC released from the hydrogel. Lane 3: ClyC free native ClyC.</p>
</caption>
<graphic xlink:href="fmats-08-763297-g004.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>The Hydrogel Maintains ClyC Antibacterial Activity <italic>in&#x20;vitro</italic>
</title>
<p>As reported before, ClyC had highly anti-bacterial against <italic>S.aureus</italic> and showed enhanced bactericidal activity in the presence of calcium. In the turbidity reduction experiment, the OD<sub>600</sub> values of T23 bacterial suspensions reduced rapidly (<xref ref-type="fig" rid="F5">Figure&#x20;5A</xref>). In support, clear zones could also be seen in the plates after dipping ClyC and ClyC-AH on the lawn of <italic>S. aureus</italic> (<xref ref-type="fig" rid="F5">Figure&#x20;5B</xref>), which showed that the released ClyC retained bactericidal activity. The bactericidal activity against <italic>S.aureus</italic> T23, by ClyC released from the hydrogel after different time intervals, was compared. The results showed that the ClyC released from hydrogel had high bactericidal activity within 24&#xa0;h. After incubation in 37&#xb0;C incubator for 24&#xa0;h, ClyC could lead to a reduction of 2.89 log<sub>10</sub> in viable cell numbers. Moreover, after incubation for 72&#xa0;h, there was still a 1.14 log<sub>10</sub> reduction in viable cells, indicating a therapeutic effect for acute infection (<xref ref-type="fig" rid="F5">Figure&#x20;5C</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>The bactericidal effect of blank hydrogel, ClyC-AH (250&#xa0;&#xb5;g/ml), and free ClyC (125&#xa0;&#xb5;g/ml) was quantified by incubating the <italic>S. aureus</italic> T23. <bold>(A)</bold> Turbidity reduction experiment, the lytic activity of ClyC and released ClyC after incubated 3&#xa0;h in 37&#xb0;C incubator; <bold>(B)</bold> inhibition zone assay result showing ClyC and ClyC-AH activity against <italic>S. aureus</italic> T23; <bold>(C)</bold> Briefly, <italic>S. aureus</italic> T23 cells at a cell density of approximately 10<sup>8</sup>&#xa0;CFU/ml were incubated with different time of sample for 1&#xa0;h at 37&#xb0;C. The lytic potential was assessed based on a decrease in bacterial log count compare with blank hydrogel after 1&#xa0;h of treatment. And the calculated result of the reduction of log<sub>10</sub> in viable cell number (&#x394;Log<sub>10</sub>&#xa0;CFU/mL). Student&#x2019;s t&#x20;test, Mean&#x20;&#xb1; SD, <italic>n</italic>&#x20;&#x3d; 3 per group, &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05.</p>
</caption>
<graphic xlink:href="fmats-08-763297-g005.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>
<italic>In vivo</italic> Treatment of Osteomyelitis With ClyC-AH</title>
<p>The osteomyelitis mouse model was established to evaluate the ability of ClyC-AH to inhibit <italic>S. aureus</italic> infection <italic>in vivo</italic>. ClyC-AH was injected into the medullary cavity using 10&#xa0;&#x3bc;L-pipet tips and subsequently transformed into hydrogels which allow stable injection into the cavity without leakage. The number of bacteria CFU in the femur and surrounding tissue was measured 7&#xa0;days after surgery to evaluate the severity of osteomyelitis. Both the infection-only and hydrogel-only groups had high number of bacteria in the femur and surrounding tissue (<xref ref-type="fig" rid="F6">Figure&#x20;6</xref>), indicating alginate hydrogels alone had no effect against <italic>S. aureus</italic>. The number of bacteria of the soluble ClyC group was significantly reduced in the surrounding tissue (<xref ref-type="fig" rid="F6">Figure&#x20;6B</xref>). For the ClyC-AH group, the amount of bacteria was significantly reduced compared with the infection-only group or the hydrogel-only group both in the femur and surrounding tissue (<xref ref-type="fig" rid="F6">Figure&#x20;6</xref>). In summary, these results demonstrated that ClyC-AH decreased <italic>S. aureu</italic>s infections, the effect of which was comparable with that of soluble&#x20;ClyC.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>ClyC-AH reduced bacteria in the infected femur. After 7&#xa0;days, <italic>S. aureus</italic> T23 recovery from <bold>(A)</bold> femur bone <bold>(B)</bold> tissue surrounding the femur. Error bars represent standard deviations. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001. Kruskal&#x2013;Wallis test with Dunn&#x2019;s multiple comparisons test for A. ANOVA with Tukey&#x2019;s <italic>post hoc</italic> test for B. Mean&#x20;&#xb1; SD, <italic>n</italic>&#x20;&#x3d; 5&#x2013;6 per&#x20;group.</p>
</caption>
<graphic xlink:href="fmats-08-763297-g006.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Bacterial infections associated with the outbreak of human diseases have developed into multidrug-resistant forms due to abuse of antibiotics, necessitating the research and development of new antibacterial agents (<xref ref-type="bibr" rid="B29">Otto, 2012</xref>). In this study, we loaded ClyC into the alginate hydrogel, which retained ClyC stability and activity while providing sustained release. Recently, some studies on the encapsulation of endolysin have been reported (<xref ref-type="bibr" rid="B15">Hathaway et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B2">Bai et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B31">Pinto et&#x20;al., 2021</xref>). Chitosan nanoparticles loaded with the Cpl-1 pneumococcal endolysin showed low cytotoxicity to lung epithelial cell lines and reduced bacterial colonization in the lungs of mice (<xref ref-type="bibr" rid="B12">Gondil et&#x20;al., 2020a</xref>). LysRODI encapsulated in pH-sensitive liposomes reduced <italic>S. aureus</italic> counts by 2log units upon incubation at pH 5 (<xref ref-type="bibr" rid="B32">Portilla et&#x20;al., 2020</xref>).</p>
<p>The delivery system enhanced the bioavailability and safety of the encapsulated protein. <italic>In vitro</italic> release studies revealed that ClyC-AH exhibited biphasic release. There was an initial rapid release, followed by slow and sustained release, which could maintain the effective ClyC concentration and avoid the rapid degradation of ClyC <italic>in vivo</italic>. The CCK-8 assay also showed that the ClyC-AH exhibited low cytotoxicity, indicating biocompatibility of ClyC-AH.</p>
<p>It is important to stably encapsulate and deliver ClyC without any adverse effects on its structure and anti-bacterial activity. SDS-PAGE analysis determined the structural integrity of ClyC. It could be explained that proteins could be incorporated into alginate hydrogel under relatively mild conditions, which was also reported by Kaur (<xref ref-type="bibr" rid="B18">Kaur et&#x20;al., 2020</xref>). The hydrogel retained the anti-bacterial activity of ClyC against <italic>S. aureus</italic> long-term <italic>in&#x20;vitro</italic>. The anti-bacterial activity of ClyC released from ClyC-AH and ClyC solutions against <italic>S. aureus</italic> was not significantly different at most time points, but the lytic speed of ClyC released from ClyC-AH tends to be slightly slower. This result might be explained by the fewer amount of ClyC released from ClyC-AH at the beginning. Sodium alginate solution can be sol-gel converted by crosslinking some divalent cations (i.e.,&#x20;Ca<sup>2&#x2b;</sup>). (<xref ref-type="bibr" rid="B21">Lee and Mooney, 2012</xref>). Interestingly, ClyC showed improved activity in the presence of calcium, with up to 9 Log<sub>10</sub> <italic>S. aureus</italic> cell reduction within 20&#xa0;min in the presence of Ca<sup>2&#x2b;</sup>, which could explain the stable ClyC activity in the hydrogel.</p>
<p>There was no evidence of endolysin resistance, which was still a potential problem. Researchers had demonstrated a synergetic approach to bacterial treatment by a combination of endolysin and antibiotics (<xref ref-type="bibr" rid="B6">Daniel et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B22">Letrado et&#x20;al., 2018</xref>). In our previous studies, we showed that penicillin G and ClyC had a synergistic effect, reducing the MIC of ClyC for planktonic and sessile <italic>S. aureus</italic> (<xref ref-type="bibr" rid="B24">Li et&#x20;al., 2021</xref>). It was beneficial to reduce the working concentration of ClyC in the lesion and weaken potential safety hazards. Next, we will further optimize ClyC-AH by combining with antibiotics to broaden the bactericidal spectrum and decrease the working concentration of&#x20;ClyC.</p>
<p>Furthermore, results of this study demonstrated antibacterial activity of ClyC-AH against <italic>S. aureus in&#x20;vivo</italic>. In a <italic>S. aureus</italic> infected mouse model, ClyC-AH significantly reduced bacterial burden compared to the hydrogel-only group. In contrast, mice treated with hydrogel showed no differences in bacterial levels in the femur and surrounding tissue compared to the bacteria-infected control group. This demonstrated that ClyC had antibacterial activity against <italic>S. aureus</italic> infection. However, our results presented one-week observation of mouse osteomyelitis model treatment, which was not enough to make a detailed conclusion. There is a need to extend the experimental period to evaluate the effect of ClyC hydrogel on bone healing and local inflammation.</p>
<p>This study demonstrated that ClyC-AH was successfully prepared by crosslinking Ca<sup>2&#x2b;</sup>, with no adverse effect on the structure of ClyC improve the anti-bacterial activity of ClyC. The delivery system could improve the biocompatibility, stability, and prolonged half-life of ClyC. Conclusively, ClyC-AH could be a promising candidate for prevention and treatment of infection caused by <italic>S. aureus.</italic>
</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusions of this article will&#x20;be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal study was reviewed and approved by the Ethics Committee for Animal Research, Wuhan University.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>YuL, QY and FY designed the project. FY, YiL and XW performed the experiments and analyzed the data. FY drafted the initial manuscript. All authors reviewed the manuscript and read the&#x20;proof.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This work was supported by National Youth Natural Science Foundation of China (No. 81901045).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdelrahman</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Easwaran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Daramola</surname>
<given-names>O. I.</given-names>
</name>
<name>
<surname>Ragab</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Oduselu</surname>
<given-names>T. J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Phage-Encoded Endolysins</article-title>. <source>Antibiotics</source> <volume>10</volume> (<issue>2</issue>), <fpage>124</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics10020124</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>P.-S.</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Preparation and Characterization of Endolysin-Containing Liposomes and Evaluation of Their Antimicrobial Activities against Gram-Negative Bacteria</article-title>. <source>Enzyme Microb. Tech.</source> <volume>128</volume>, <fpage>40</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.enzmictec.2019.05.006</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Bubeck Wardenburg</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>
<italic>Staphylococcus aureus</italic> and the Skin: a Longstanding and Complex Interaction</article-title>. <source>Skinmed</source> <volume>13</volume> (<issue>2</issue>), <fpage>111</fpage>&#x2013;<lpage>120</lpage>. </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassat</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Skaar</surname>
<given-names>E. P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Recent Advances in Experimental Models of Osteomyelitis</article-title>. <source>Expert Rev. Anti-infective Ther.</source> <volume>11</volume> (<issue>12</issue>), <fpage>1263</fpage>&#x2013;<lpage>1265</lpage>. <pub-id pub-id-type="doi">10.1586/14787210.2013.858600</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conterno</surname>
<given-names>L. O.</given-names>
</name>
<name>
<surname>Turchi</surname>
<given-names>M. D.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Antibiotics for Treating Chronic Osteomyelitis in Adults</article-title>. <source>Cochrane Database Syst. Rev.</source> <volume>9</volume>, <fpage>Cd004439</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD004439.pub3</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daniel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Euler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Collin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chahales</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gorelick</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Fischetti</surname>
<given-names>V. A.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant <italic>Staphylococcus aureus</italic>
</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>54</volume> (<issue>4</issue>), <fpage>1603</fpage>&#x2013;<lpage>1612</lpage>. <pub-id pub-id-type="doi">10.1128/aac.01625-09</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davies</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Origins and Evolution of Antibiotic Resistance</article-title>. <source>Microbiol. Mol. Biol. Rev.</source> <volume>74</volume> (<issue>3</issue>), <fpage>417</fpage>&#x2013;<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1128/mmbr.00016-10</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Delivery of Alginate-Chitosan Hydrogel Promotes Endogenous Repair and Preserves Cardiac Function in Rats with Myocardial Infarction</article-title>. <source>J.&#x20;Biomed. Mater. Res.</source> <volume>103</volume> (<issue>3</issue>), <fpage>907</fpage>&#x2013;<lpage>918</lpage>. <pub-id pub-id-type="doi">10.1002/jbm.a.35232</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Sustained Release of Bioactive IGF-1 from a Silk Fibroin Microsphere-Based Injectable Alginate Hydrogel for the Treatment of Myocardial Infarction</article-title>. <source>J.&#x20;Mater. Chem. B</source> <volume>8</volume> (<issue>2</issue>), <fpage>308</fpage>&#x2013;<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1039/c9tb01971e</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fowler</surname>
<given-names>V. G.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Das</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Lipka-Diamond</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schuch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pomerantz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>J&#xe1;uregui-Peredo</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Exebacase for Patients with <italic>Staphylococcus aureus</italic> Bloodstream Infection and Endocarditis</article-title>. <source>J.&#x20;Clin. Invest.</source> <volume>130</volume> (<issue>7</issue>), <fpage>3750</fpage>&#x2013;<lpage>3760</lpage>. <pub-id pub-id-type="doi">10.1172/jci136577</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gimza</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Cassat</surname>
<given-names>J.&#x20;E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mechanisms of Antibiotic Failure during <italic>Staphylococcus aureus</italic> Osteomyelitis</article-title>. <source>Front. Immunol.</source> <volume>12</volume>, <fpage>638085</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.638085</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gondil</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Dube</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Panda</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Yennamalli</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Harjai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chhibber</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020a</year>). <article-title>Comprehensive Evaluation of Chitosan Nanoparticle Based Phage Lysin Delivery System; a Novel Approach to Counter S. Pneumoniae Infections</article-title>. <source>Int. J.&#x20;Pharmaceutics</source> <volume>573</volume>, <fpage>118850</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.118850</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gondil</surname>
<given-names>V. S.</given-names>
</name>
<name>
<surname>Harjai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chhibber</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020b</year>). <article-title>Endolysins as Emerging Alternative Therapeutic Agents to Counter Drug-Resistant Infections</article-title>. <source>Int. J.&#x20;Antimicrob. Agents</source> <volume>55</volume> (<issue>2</issue>), <fpage>105844</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2019.11.001</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haddad Kashani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schmelcher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sabzalipoor</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Seyed Hosseini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Moniri</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Recombinant Endolysins as Potential Therapeutics against Antibiotic-Resistant <italic>Staphylococcus aureus</italic>: Current Status of Research and Novel Delivery Strategies</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>31</volume> (<issue>1</issue>). <pub-id pub-id-type="doi">10.1128/cmr.00071-17</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hathaway</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Bean</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Esteban</surname>
<given-names>P. P.</given-names>
</name>
<name>
<surname>Ouadi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mark Sutton</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Poly(N-isopropylacrylamide-co-allylamine) (PNIPAM-Co-ALA) Nanospheres for the Thermally Triggered Release of Bacteriophage K</article-title>. <source>Eur. J.&#x20;Pharmaceutics Biopharmaceutics</source> <volume>96</volume>, <fpage>437</fpage>&#x2013;<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2015.09.013</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Wroe</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Guldberg</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Donlan</surname>
<given-names>R. M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Hydrogel Delivery of Lysostaphin Eliminates Orthopedic Implant Infection by <italic>Staphylococcus aureus</italic> and Supports Fracture Healing</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>115</volume> (<issue>22</issue>), <fpage>E4960</fpage>&#x2013;<lpage>e4969</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1801013115</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jun</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>I. J.</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>K.-S.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J.&#x20;Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration Among Healthy Volunteers</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>61</volume> (<issue>6</issue>), <fpage>e02629</fpage>. <pub-id pub-id-type="doi">10.1128/aac.02629-16</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaur</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kour</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Panda</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Harjai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chhibber</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Exploring Endolysin-Loaded Alginate-Chitosan Nanoparticles as Future Remedy for Staphylococcal Infections</article-title>. <source>AAPS PharmSciTech</source> <volume>21</volume> (<issue>6</issue>), <fpage>233</fpage>. <pub-id pub-id-type="doi">10.1208/s12249-020-01763-4</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klopfenstein</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cassat</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Monteith</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Drury</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Skaar</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Murine Models for Staphylococcal Infection</article-title>. <source>Curr. Protoc.</source> <volume>1</volume> (<issue>3</issue>), <fpage>e52</fpage>. <pub-id pub-id-type="doi">10.1002/cpz1.52</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kremers</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Nwojo</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Ransom</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Wood-Wentz</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Melton</surname>
<given-names>L. J.</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Huddleston</surname>
<given-names>P. M.</given-names>
<suffix>3rd</suffix>
</name>
</person-group> (<year>2015</year>). <article-title>Trends in the Epidemiology of Osteomyelitis</article-title>. <source>J.&#x20;Bone Jt. Surg.</source> <volume>97</volume> (<issue>10</issue>), <fpage>837</fpage>&#x2013;<lpage>845</lpage>. <pub-id pub-id-type="doi">10.2106/jbjs.N.01350</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>K. Y.</given-names>
</name>
<name>
<surname>Mooney</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Alginate: Properties and Biomedical Applications</article-title>. <source>Prog. Polym. Sci.</source> <volume>37</volume> (<issue>1</issue>), <fpage>106</fpage>&#x2013;<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1016/j.progpolymsci.2011.06.003</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letrado</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Corsini</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>D&#xed;ez-Mart&#xed;nez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bustamante</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yuste</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<name>
<surname>Garc&#xed;a</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Bactericidal Synergism between Antibiotics and Phage Endolysin Cpl-711 to Kill Multidrug-Resistant Pneumococcus</article-title>. <source>Future Microbiol.</source> <volume>13</volume> (<issue>11</issue>), <fpage>1215</fpage>&#x2013;<lpage>1223</lpage>. <pub-id pub-id-type="doi">10.2217/fmb-2018-0077</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lew</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Waldvogel</surname>
<given-names>F. A.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Osteomyelitis</article-title>. <source>The Lancet</source> <volume>364</volume> (<issue>9431</issue>), <fpage>369</fpage>&#x2013;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(04)16727-5</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nyaruaba</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>A Highly Active Chimeric Lysin with a Calcium-Enhanced Bactericidal Activity against <italic>Staphylococcus aureus In Vitro</italic> and <italic>In Vivo</italic>
</article-title>. <source>Antibiotics</source> <volume>10</volume> (<issue>4</issue>), <fpage>461</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics10040461</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindsay</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Holden</surname>
<given-names>M. T. G.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>
<italic>Staphylococcus aureus</italic> : Superbug, Super Genome?</article-title> <source>Trends Microbiol.</source> <volume>12</volume> (<issue>8</issue>), <fpage>378</fpage>&#x2013;<lpage>385</lpage>. <pub-id pub-id-type="doi">10.1016/j.tim.2004.06.004</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lowy</surname>
<given-names>F. D.</given-names>
</name>
</person-group> (<year>1998</year>). <article-title>Staphylococcus aureusInfections</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>339</volume> (<issue>8</issue>), <fpage>520</fpage>&#x2013;<lpage>532</lpage>. <pub-id pub-id-type="doi">10.1056/nejm199808203390806</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maffulli</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Papalia</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zampogna</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Albo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Denaro</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The Management of Osteomyelitis in the Adult</article-title>. <source>The Surgeon</source> <volume>14</volume> (<issue>6</issue>), <fpage>345</fpage>&#x2013;<lpage>360</lpage>. <pub-id pub-id-type="doi">10.1016/j.surge.2015.12.005</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munita</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Arias</surname>
<given-names>C. A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Mechanisms of Antibiotic Resistance</article-title>. <source>Microbiol. Spectr.</source> <volume>4</volume> (<issue>2</issue>), <fpage>481</fpage>&#x2013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1128/microbiolspec.VMBF-0016-2015</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otto</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>MRSA Virulence and Spread</article-title>. <source>Cell Microbiol</source> <volume>14</volume> (<issue>10</issue>), <fpage>1513</fpage>&#x2013;<lpage>1521</lpage>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2012.01832.x</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pantosti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sanchini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Mechanisms of Antibiotic Resistance in <italic>Staphylococcus aureus</italic>
</article-title>. <source>Future Microbiol.</source> <volume>2</volume> (<issue>3</issue>), <fpage>323</fpage>&#x2013;<lpage>334</lpage>. <pub-id pub-id-type="doi">10.2217/17460913.2.3.323</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Pastrana</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Ba&#xf1;obre-L&#xf3;pez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sillankorva</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Clinical Path to Deliver Encapsulated Phages and Lysins</article-title>. <source>FEMS Microbiol. Rev.</source> <volume>19</volume>, <fpage>1</fpage>&#x2013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1093/femsre/fuab019</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Portilla</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guti&#xe9;rrez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rodr&#xed;guez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garc&#xed;a</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Encapsulation of the Antistaphylococcal Endolysin LysRODI in pH-Sensitive Liposomes</article-title>. <source>Antibiotics</source> <volume>9</volume> (<issue>5</issue>), <fpage>242</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics9050242</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pugliese</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Favero</surname>
<given-names>M. S.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Outbreaks of Community-Associated Methicillin-Resistant <italic>Staphylococcus aureus</italic> Skin Infections</article-title>. <source>Infect. Control. Hosp. Epidemiol.</source> <volume>24</volume> (<issue>10</issue>), <fpage>787</fpage>. <pub-id pub-id-type="doi">10.1086/infeconthospepid.24.10.787</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Resch</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Moreillon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fischetti</surname>
<given-names>V. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>A Stable Phage Lysin (Cpl-1) Dimer with Increased Antipneumococcal Activity and Decreased Plasma Clearance</article-title>. <source>Int. J.&#x20;Antimicrob. Agents</source> <volume>38</volume> (<issue>6</issue>), <fpage>516</fpage>&#x2013;<lpage>521</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2011.08.009</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruvinov</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Alginate Biomaterial for the Treatment of Myocardial Infarction: Progress, Translational Strategies, and Clinical Outlook</article-title>. <source>Adv. Drug Deliv. Rev.</source> <volume>96</volume>, <fpage>54</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2015.04.021</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seijsing</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sobieraj</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zinkernagel</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Loessner</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Improved Biodistribution and Extended Serum Half-Life of a Bacteriophage Endolysin by Albumin Binding Domain Fusion</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>, <fpage>2927</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.02927</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Urish</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Cassat</surname>
<given-names>J.&#x20;E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>
<italic>Staphylococcus aureus</italic> Osteomyelitis: Bone, Bugs, and Surgery</article-title>. <source>Infect. Immun.</source> <volume>88</volume> (<issue>7</issue>), <fpage>e00932</fpage>. <pub-id pub-id-type="doi">10.1128/iai.00932-19</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varaprasad</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jayaramudu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kanikireddy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Toro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sadiku</surname>
<given-names>E. R.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Alginate-based Composite Materials for Wound Dressing Application:A Mini Review</article-title>. <source>Carbohydr. Polym.</source> <volume>236</volume>, <fpage>116025</fpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2020.116025</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>